TRASTUZUMAB PACKAGE INSERT NO FURTHER A MYSTERY

One of the more less than-investigated “driving forces” involved with trastuzumab resistance is PTEN. Nagata et al. (2004) claimed which the loss of PTEN was observed in 36% of HER2-positive Key breast tumor specimens from sufferers with phase IV illness. In addition, Additionally they confirmed that sufferers with PTEN-deficient tumors experie